Novartis NVS shares are trading higher on Wednesday after the company announced it received FDA approval for its Cosentyx for a new indication to treat active non-radiographic axial spondyloarthritis.
Novartis develops and manufactures health care products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines.
The company sells its products globally, with the United States representing close to one third of total sales.
Novartis shares were trading up 3.13% at $89.41 at time of publication on Wednesday. The stock has a 52-week high of $99.84 and a 52-week low of $69.18.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
